News

The Parkinson Voice Project (PVP) is hosting a complimentary educational lecture that will focus on optimizing exercise strategies for Parkinson’s disease patients and caregivers. The presentation “Packing Some ‘Punch’ Into Your Parkinson’s Exercise Routine” will take place at 10:30 a.m. CST Feb. 9 at PVP, in Richardson, Texas.

An investigational gene therapy was able to preserve nerve axons — long projections that connect nerve cells and transport information — in a mouse model of severe axonal degeneration. Because axon degeneration precedes the death of neurons in several neurodegenerative diseases, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS), the findings…

Neurocrine Biosciences and Voyager Therapeutics have joined efforts in a new strategic collaboration to further develop and market Voyager’s gene therapies VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia. With this partnership, Neurocrine Biosciences will apply its expertise in neuroscience, drug development, and…

A “PACT” formed by the Parkinson’s community — to prevent, advocate for increased resources, care for all those affected, and treat with new therapies — may help prevent a Parkinson’s pandemic, according to a review study. The study, “The Emerging Evidence of the Parkinson Pandemic,” appeared in…

This year, Parkinson Voice Project (PVP) is broadening its SPEAK OUT! & LOUD Crowd Grant Program to include support for international speech therapy clinics. The expanded grant program is intended to help Parkinson’s disease patients around the world gain access to quality speech treatment to maintain their speaking abilities and…

Use of dopamine agonists, earlier disease onset, being male, and having personality traits such as impulsiveness and high novelty-seeking are among the risk factors for developing impulse control disorders (ICDs) in people with Parkinson’s, according to a review study. The research, “Impulse control disorders in Parkinson’s…